Promising Therapeutic Developments for TDP-Related Pathologies: Sílvia Porta, PhD
July 21st 2023The research assistant professor, pathology and laboratory medicine, University of Pennsylvania, talked about the ongoing research in her lab on understanding the mechanisms and consequences of TDP-43 aggregation in Alzheimer Disease. [WATCH TIME: 4 minutes]
Revolutionizing Alzheimer Disease Diagnosis with Blood Biomarkers: Nicholas Ashton, PhD
July 20th 2023The associate professor of neurochemistry at the University of Gothenburg in Sweden talked about a pilot study that explored the potential of finger prick tests to remotely collect blood and provide reliable biomarker results for Alzheimer disease diagnosis. [WATCH TIME: 5 minutes]
Screening for Alzheimer Disease: Facilitating an Early Diagnosis for Prompt Intervention
July 20th 2023In this episode of MEDcast, expert geriatric psychiatrists explore the urgent need for effective diagnostic methods that can detect Alzheimer’s disease at an early stage. We will discuss blood-based biomarkers and other advancements that can help screen Alzheimer’s disease non-invasively and early in the disease course.
Overcoming Complexities With Cognitive Screening in Primary Care Centers: Nicole Fowler, PhD
July 20th 2023The director of research for internal medicine and geriatrics at Indiana University School of Medicine provided perspective on ways to effectively streamline cognitive screening in timely and accurate manor. [WATCH TIME: 4 minutes]
Opioid Use and Mortality Risk in Older Patients with Dementia: Christina Jensen-Dahm, MD, PhD
July 19th 2023The neurologist in the Danish Dementia Research Center at Rigshospitalet in Copenhagen, Denmark, discussed a cohort study that examined the association between opioid use and the risk of mortality in an older patient population living with dementia. [WATCH TIME: 5 minutes]
Access to and Challenges to Biosimilar use in Clinical Practice
John Kramer, PA-C, Patricia Melville, NP-C, and Amy Perrin Ross, APN identify challenges in accessing biosimilars in clinical practice.
Comparison of AFFIRM (Reference Natalizumab) and Antelope (Biosimilar Natalizumab) Trials
Aliza Ben-Zacharia, PhD, DNP, ANP-BC and Amy Perrin Ross, APN discuss differences between biologic and biologic natalizumab phase 3 trials.
Implications of Rising Alzheimer Disease Prevalence Across US Counties: Kumar B. Rajan, PhD
July 18th 2023The professor in the department of internal medicine at RUSH Medical College talked about estimating the prevalence of Alzheimer disease to uncover the variability in disease prevalence at a micro-level and its implications for public health programs. [WATCH TIME: 5 minutes]
Differences in Available Cognitive Screening Tools: Dustin Hammers, PhD
July 17th 2023The associate professor of neurology at the Indiana University School of Medicine provided insight on the distinguishable characteristics of certain cognitive screening tools and the advantages to each. [WATCH TIME: 3 minutes]
Preparing Primary Care Centers for New Wave of Alzheimer Agents: Nicole Fowler, PhD, MHSA
July 17th 2023The director of research for internal medicine and geriatrics at Indiana University School of Medicine provided perspective on navigating challenges with newly approved treatments for Alzheimer disease, and using resources efficiently. [WATCH TIME: 5 minutes]
Mechanistic Effectiveness of Combined Approach With Nusinersen and Zolgensma: Crystal Proud, MD
July 13th 2023The director of neurology and neuromuscular medicine at the Children’s Hospital of the King’s Daughters in Norfolk, Virginia, provided background on findings from the phase 4 RESPOND study, and the potential of combining therapeutic approaches in SMA. [WATCH TIME: 4 minutes]
Identifying Effective Big Data Techniques to Address Heterogeneity in Migraine: Ali Ezzati, MD
July 13th 2023The director of the Neuroinformatics Program at the University of California, Irvine, discussed complexities with different machine learning algorithms in migraine research, including findings from the AMPP study. [WATCH TIME: 5 minutes]
Examining Depression and Suicidality in Pediatric Patients With MS: Sarah C. Stoney, MSW, LSW
July 12th 2023The social worker in the Pediatric Multiple Sclerosis Clinic at Children's Hospital of Philadelphia talked about depression and suicidality rates in pediatric patients with multiple sclerosis. [WATCH TIME: 5 minutes]
Efforts Needed to Reach Underserved Communities, Advance Pain Medicine Research: Burel Goodin, PhD
July 12th 2023The professor of anesthesiology at Washington University in St. Louis discussed the reasons behind his presentation at the 2023 AHS Annual Meeting on engaging underserved populations in pain medicine research. [WATCH TIME: 3 minutes]
Natalizumab Biosimilar in Development in Multiple Sclerosis
Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C discuss natalizumab biosimilar (biosim-NTZ) PB006 phase 3 Antelope study.
Cost Savings with Biosimilars and Use in Multiple Sclerosis
Advanced practice providers discuss potential cost savings with biosimilars and biosimilar use in multiple sclerosis.
Pregnancy and Family Planning Considerations When Treating Patients With Multiple Sclerosis
July 11th 2023In this episode of MEDcast, Dr Krieger, Dr Brandstadter, and Dr Bove discuss MS care in patients who are considering pregnancy. They highlight treatment options, monitoring recommendations during and after pregnancy, as well as other crucial considerations when caring for patients with childbearing goals.
Finding More Creative and Effective Ways to Teach Neurology: Alexandria Reynolds, PhD
July 10th 2023The undergraduate program director at the University of South Carolina discussed outdated teaching methods used in neurology, and the need to provide different hands-on approaches to students. [WATCH TIME: 5 minutes]
Prospects for Improving Cognitive Impairment in Early MS With Ozanimod: Robert Zivadinov, MD, PhD
July 9th 2023The director of the Buffalo Neuroimaging Analysis Center talked about the ENLIGHTEN trial, where results showed a correlation between cognitive impairment and brain volume with ozanimod. [WATCH TIME: 5 minutes]